Is Quick Heal Tech overvalued or undervalued?

As of 5 February 2025, Quick Heal Technologies Ltd. has moved from a valuation grade of very expensive to risky, indicating a significant shift in its market perception. The company is currently considered overvalued, particularly highlighted by its PE ratio of 393.95 and an EV to EBITDA ratio of -272.02, which suggests severe profitability concerns. Additionally, the ROCE stands at -7.86%, further emphasizing the challenges the company faces in generating returns on capital.
In comparison to its peers, Quick Heal's valuation metrics are starkly unfavorable; for instance, its PE ratio is substantially higher than industry averages, while its EV to EBITDA is negative, indicating potential operational inefficiencies. Notably, the company’s PEG ratio is 0.00, which raises questions about future growth prospects. Despite a recent surge in stock price, with a 1-week return of 22.18% compared to the Sensex's 1.38%, the overall valuation suggests that Quick Heal Technologies Ltd. remains overvalued in the current market landscape.